1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl] -N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 231-238

  Hori, Yasunobu ^a   Imanishi, Akio ^a   Matsukawa, Jun ^a   Tsukimi, Yasuhiro ^a   Nishida, Haruyuki ^a   Arikawa, Yasuyoshi ^a   Hirase, Keizo ^a   Kajino, Masahiro ^a   Inatomi, Nobuhiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (2 FLUOROPHENYL) 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE MONOFUMARATE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; FUMARIC ACID DERIVATIVE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER; TAK 438; UNCLASSIFIED DRUG; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DITHIOTHREITOL; HISTAMINE; IMIDAZOLE DERIVATIVE; POTASSIUM; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; IC 50; MICROSOME; NONHUMAN; PH; PRIORITY JOURNAL; RAT; STOMACH ACID SECRETION; SWINE; ANIMAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; IN VITRO STUDY; KINETICS; LIGATION; MALE; METABOLISM; PYLORUS; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; STOMACH; STOMACH ACID; STOMACH MUCOSA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; DITHIOTHREITOL; GASTRIC ACID; GASTRIC MUCOSA; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; KINETICS; LIGATION; MALE; POTASSIUM; PROTON PUMP INHIBITORS; PYLORUS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; STOMACH; SULFONAMIDES; SWINE; IN VITRO TECHNIQUES; LANSOPRAZOLE;

EID: 77957228369     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170274     Document Type: Article

References (38)

1. Andersson K and Carlsson E (2005) Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 108:294-307.
2. Ang TL and Fock KM (2006) Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 21 (Suppl 5):125-128.
3. Bell NJ, Burget D, Howden CW, Wilkinson J, and Hunt RH (1992) Appropriate acid suppression for management of gastro-esophageal reflux disease. Digestion 51 (Suppl 1):59-67.
4. Dammann HG and Burkhardt F (1999) Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 11:1277-1282.
5. Dent J, El-Serag HB, Wallander MA, and Johansson S (2005) Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54:710-717.
6. Fass R, Shapiro M, Dekel R, and Sewell J (2005) Proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 22:79-94.
7. Fiske CH and Subbarow Y (1925) The colorimetric determination of phosphorus. J Biol Chem 66:375-400.
8. Frazzoni M, De Micheli E, Grisendi A, and Savarino V (2003) Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 17:235-241.
9. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, and Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153-167.
10. +-ATPase. Biochem Pharmacol 73:198-205.
11. Geibel JP (2005) Role of potassium in acid secretion. World J Gastroenterol 11:5259-5265.
12. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, and Huang B (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169-175.
13. + ATPase in human tissue. Scand J Gastroenterol 42:1275-1288.
14. Hunt RH (1999) Importance of pH control in the management of GERD. Arch Intern Med 159:649-657.
15. Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, and Shibakawa N (2007) Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl] methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther 323:308-317.
16. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S, and Hasselgren G (2007) A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5:1385-1391.
17. Katz PO, Hatlebakk JG, and Castell DO (2000) Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 14:709-714.
18. Katz PO, Scheiman JM, and Barkun AN (2006) Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 23:9-22.
19. Malfertheiner P, MOssner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, and Fuchs W (2003) Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 18:615-625.
20. +-ATPase. J Biol Chem 265:5030-5036.
21. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 248:799-805.
22. Nagaya H, Satoh H, and Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295.
23. 2-receptor antagonist famotidine in rats and dogs. Jpn J Pharmacol 55:425-436.
24. Parsons ME and Keeling DJ (2005) Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 14:411-421.
25. +)-ATPase, SK&F 97574: I. In vitro activity. Biochem Pharmacol 50:1543-1549.
26. Robinson M (2005) Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 59:709-715.
27. Sachs G, Carlsson E, Lindberg P, and Wallmark B (1988) Gastric H, K-ATPase as therapeutic target. Ann Rev Pharmacol Toxicol 28:269-284.
28. +-ATPase. Annu Rev Pharmacol Toxicol 35:277-305.
29. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, and Maki Y (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 248:806-815.
30. +-competitive acid blocker TAK-438. Gastroenterol 138:S651-S652.
31. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, and Senn-Bilfinger J, and Postius S (2007) Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 321:866-874.
32. +-ATPase inhibitor SPI-447. Jpn J Pharmacol 82:21-28.
33. Tytgat GN (2001) Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 13:S29-S33.
34. Vakil N (2004) Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 19:1041-1049.
35. +-ATPase and acid secretion by SCH28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 262:2077-2084.
36. Wolfe MM and Sachs G (2000) Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterol 118:S9-S31.
37. Wurst W and Hartmann M (1996) Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med 69:233-243.
38. Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, et al. (2004) Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 44:73-82.